Sector News

Forma’s John Hohneker takes the reins at Anokion

January 18, 2018
Life sciences

After shepherding Forma Therapeutics from its discovery stage to clinical trials as its R&D chief, John Hohneker is joining Anokion Therapeutics as president and CEO, effective Jan. 22.

“John brings tremendous experience in biologics development to Anokion, including in the immunology space. His broad leadership in both preclinical and clinical development will strengthen Anokion’s powerful platforms in immunological tolerance,” said Jeffrey Hubbell, the academic founder, chairman and chief scientific officer of Anokion, in a statement.

Anokion, a spinout of the Ecole Polytechnique Fédérale de Lausanne in Switzerland, is working on an antigen-specific immune tolerance platform for the development of new treatments for autoimmune disease.

The tech is designed for “diverse applications,” the company says, including tolerizing the immune system to self-antigens behind autoimmune diseases, as well as cutting the immunogenicity of therapeutic proteins.

The biotech is advancing two approaches to exploit the body’s natural tolerance mechanism of apoptotic, or aging, cells. Both involve engineering antigens to provoke a tolerogenic immune response—in the first, the antigens bind to a surface protein unique to red blood cells, while in the second, they bind to liver cells.

In addition to his R&D experience at Forma, Hohneker served in a number of roles at Novartis, most recently as senior vice president and global head of development for immunology and dermatology.

In January last year, Celgene plunked down $45 million up front to join forces with Anokion on tolerance-inducing treatments. Anokion stands to collect another $10 million if it hits certain preclinical performance marks, while Celgene picked up an equity interest in Anokion and the exclusive right to acquire the biotech at a later date.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach